Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.19.3.a.u2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2019
Dec. 31, 2018
Current assets    
Cash $ 1,148 $ 89
Prepaid expenses 12,531 12,991
Total current assets 13,679 13,080
Total Assets 13,679 13,080
Current liabilities    
Accounts payable 173,973 191,714
Accrued expenses 419,251 421,000
Accrued interest payable 572,975 537,118
Related party payables 1,412,868 1,423,984
Derivative liabilities 28,800
Stock subscriptions payable 1,674 1,271
Notes payable - current - related parties *Includes unamortized debt issuance costs related to detached warrants of $23,757 and $8,074 at March 31, 2019 and December 31, 2018, respectively 726,837 697,770
Notes payable - current - non related parties * Includes unamortized beneficial conversion features related to convertible notes of $28,564 and $5,920 at March 31, 2019 and December 31, 2018, respectively 170,010 163,654
Total current liabilities 3,506,388 3,436,511
Total Liabilities 3,506,388 3,436,511
Stockholders' Deficit    
Preferred stock, $0.00001 par value; 22,000,000 shares authorized, No shares issued or outstanding as of March 31, 2019 and December 31, 2018
Common stock, $0.00001 par value; 800,000,000 shares authorized; 152,205,625 and 109,409,930 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively 1,522 1,172
Additional paid-in capital 14,957,232 14,887,804
Accumulated deficit (18,400,425) (18,262,136)
Total Transbiotec, Inc. stockholders' deficit (3,441,657) (3,373,146)
Noncontrolling interest (51,052) (50,285)
Total Stockholders' Deficit (3,492,709) (3,423,431)
Total Liabilities and Stockholders' Deficit 13,679 13,080
Series A Convertible Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock, $0.00001 par value; 22,000,000 shares authorized, No shares issued or outstanding as of March 31, 2019 and December 31, 2018 $ 14 $ 14